- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Do JAK-STAT Inhibitors confer increased risk of vascular complications in dermatology patients?
![Do JAK-STAT Inhibitors confer increased risk of vascular complications in dermatology patients? Do JAK-STAT Inhibitors confer increased risk of vascular complications in dermatology patients?](https://medicaldialogues.in/h-upload/2024/02/02/750x450_231394-jak-stat-inhibitors.webp)
Australia: Evolving evidence suggests that dermatology patients receiving Janus kinase-signal transducer and activator of transcription inhibitors (JAK-STATi) may be at increased risk of venous thromboembolism (VTE) and major adverse cardiovascular events (MACE). Most existing literature focused on indications that may confer a higher risk of MACE and VTE than that among patients with isolated dermatological indications.
A recent meta-analysis of randomized clinical trials did not identify a significant rise in the risk of VTE and MACE in dermatology patients receiving JAK-STATi for a median duration of 16 weeks.
The results of the review published in JAMA Dermatology suggest that the evidence is insufficient regarding an increased risk of cardiovascular complications conferred by JAK-STATi in dermatological patients, particularly when used for short time frames.
JAK-STATi include Janus kinase and tyrosine kinase 2 (TYK2) inhibitors, medications that target the JAK-STAT pathway; a series of intracellular mediators that result in amplification and gene transcription through a secondary messenger pathway. Over the past decade, JAK-STATi has revolutionized the management of several dermatological conditions.
In 2022, the ORAL study, a large open-label randomized clinical trial, suggested that rheumatoid arthritis patients receiving JAK-STATi may be at higher risk of MACE and VTE. This prompted a classwide black box warning counselling against their use in patients above 65 years or with preexisting cardiovascular risk factors. Similarly, dermatological guidelines have recommended against JAK-STATi use in certain population groups, or only in patients who have failed trials of more established therapies, including TNF inhibitors.
Against the above background, Patrick A. Ireland, Prince of Wales Hospital, Randwick, New South Wales, Australia, and colleagues aimed to evaluate the risk of VTE, MACE, serious adverse events (SAEs), and tolerability of systemic JAK-STATi compared with placebo, in those with a dermatologic indication.
For this purpose, the researchers carried out a systematic review of the literature from June 2023 using online databases. The analysis was reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines.
The eligibility criteria of the studies were placebo-controlled randomized clinical trials that compared systemic JAK-STATi with placebo and investigated the safety in patients with atopic dermatitis, vitiligo, psoriasis, alopecia areata, lichen planus or hidradenitis suppurativa. Study selection and data extraction were carried out by two authors working independently using a standardized template.
The main outcomes were the incidence of VTE, SAE, MACE, and study discontinuation due to TEAEs. Analysis of these values was done against person exposure years to determine the incidence rate (IR). Risk ratios (RRs) compared incidence rates among treatment and placebo comparator arms.
The researchers reported the following findings:
- Forty-five randomized clinical trials were eligible for inclusion, with 12 996 patients receiving active JAK-STATi therapy and 4925 allocated to placebo treatment.
- There was no significant increase in MACE (I2 = 0.00%; RR, 0.47) or VTE (I2 = 0.00%; RR, 0.46) between placebo and JAK-STATi comparator arms.
- There was also no significant difference in SAEs (I2 = 12.38%; RR, 0.92) and discontinuations between JAK-STATi and placebo (I2 = 23.55%; RR, 0.94).
"We did not identify a significant increase in the risk of MACE and VTE in dermatology patients receiving JAK-STATi in the short term," the researchers wrote.
The results aid in reassuring clinicians that prescribing these medications in short intervals to patients with low CV risk profiles appears to be both well tolerated and safe in this cohort.
"Given the limited evidence, clinicians must remain judicious in their use of these medications for long durations and in high-risk patient populations," the research team concluded.
Reference:
Ireland PA, Jansson N, Spencer SKR, Braden J, Sebaratnam D. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials. JAMA Dermatol. Published online January 31, 2024. doi:10.1001/jamadermatol.2023.5509
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751